Patents by Inventor Moriya Tsuji

Moriya Tsuji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycolipids and analogues thereof as antigens for NK T cells
    Patent number: 7534434
    Abstract: This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: May 19, 2009
    Assignees: The Rockefeller University, The Scripps Research Insititute
    Inventors: Moriya Tsuji, David D. Ho, Chi-Huey Wong, Doug Wu, Masakazu Fujio
  • GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS
    Publication number: 20090117089
    Abstract: This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Application
    Filed: September 18, 2006
    Publication date: May 7, 2009
    Applicant: The Rockefeller University
    Inventors: Ralph M. Steinman, Kang Liu, Moriya Tsuji
  • Use of glycosylceramides as adjuvants for vaccines against infections and cancer
    Patent number: 7488491
    Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably ?-galactosylceramide (?-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: February 10, 2009
    Assignee: New York University
    Inventors: Moriya Tsuji, Gloria Gonzalez-Aseguinolaza, Yasuhiko Koezuka
  • Glycolipids And Analogues Thereof As Antigens For NKT Cells
    Publication number: 20070238871
    Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Application
    Filed: April 13, 2007
    Publication date: October 11, 2007
    Applicants: THE ROCKEFELLER UNIVERSITY, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Moriya Tsuji, David Ho, Chi-Huey Wong, Douglass Wu, Masakazu Fujio
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
    Patent number: 7273852
    Abstract: The invention is directed to compounds of formula (I) wherein X is O or NH; R? is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q? is optionally present and may be a C1-10 hydrocarbon; X? is optionally present and may be O, S or NR8; and Q3 may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: September 25, 2007
    Assignee: The Research Foundation of the City University of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard Franck, Guangli Yang
  • Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
    Publication number: 20060240033
    Abstract: The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen by conjointly administering an allogenic or syngenic MHC molecule (as a universal adjuvant) to trigger a local inflammatory reaction to enhance antigen presentation at the site of delivery.
    Type: Application
    Filed: April 25, 2006
    Publication date: October 26, 2006
    Applicant: New York University
    Inventor: Moriya Tsuji
  • Glycolipids and analogues thereof as antigens for NK T cells
    Publication number: 20060211856
    Abstract: This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Application
    Filed: December 27, 2005
    Publication date: September 21, 2006
    Inventors: Moriya Tsuji, David Ho, Chi-Huey Wong, Doug Wu, Masakazu Fujio
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases
    Publication number: 20060019246
    Abstract: The invention is directed to compounds of formula (I) wherein X is O or NH; R? is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q? is optionally present and may be a C1-10 hydrocarbon; X? is optionally present and may be O, S or NR8; and Q3 may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
    Type: Application
    Filed: July 29, 2005
    Publication date: January 26, 2006
    Applicants: New York University, Research Foundation of the City University of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard Franck, Guangli Yang
  • Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
    Publication number: 20050222048
    Abstract: The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R3 is OH or a monosaccharide and R4 is hydrogen, or R3 is hydrogen and R4 is OH or a monosaccharide; R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 6, 2005
    Applicants: The Research Foundation of The City University of New York, New York University
    Inventors: Moriya Tsuji, Richard Franck, Guangwu Chen
  • Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
    Publication number: 20050192248
    Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
    Type: Application
    Filed: October 8, 2004
    Publication date: September 1, 2005
    Applicant: NYU Medical Center
    Inventors: Moriya Tsuji, John Schmieg, Richard Franck, Yaoxing Huang
  • Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
    Publication number: 20040127429
    Abstract: The invention is directed to compounds of formula (I) 1
    Type: Application
    Filed: June 13, 2003
    Publication date: July 1, 2004
    Inventor: Moriya Tsuji
  • Use of glycosylceramides as adjuvants for vaccines against infections and cancer
    Publication number: 20030157135
    Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably &agr;-galactosylceramide (&agr;-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
    Type: Application
    Filed: July 25, 2002
    Publication date: August 21, 2003
    Applicant: NEW YORK UNIVERSITY
    Inventors: Moriya Tsuji, Gloria Gonzalez-Aseguinolaza, Yasuhiko Koezuka